BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
SUBSCRIBE
BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
BullScope
No Result
View All Result
Home Bargains & Bubbles

Zoetis: The Business Keeps Earning. The Price Keeps Falling. The Gap Between the Two Is Unusually Wide.

Moe Alsumidaie by Moe Alsumidaie
November 10, 2026
in Bargains & Bubbles
0
75
SHARES
1.3k
VIEWS
Share on XShare on LinkedInShare on Facebook

For most of its decade as a public company, Zoetis traded like a luxury good, priced as if its grip on the animal-health market was permanent and its growth was guaranteed. Veterinary clinics stocked its dermatology drugs, farmers relied on its livestock vaccines, and investors paid a premium for the predictability. Then 2026 arrived with generic competitors, price-sensitive pet owners, and a stock that has shed nearly a third of its value in twelve months, landing at $82.32 as of November 10. The business did not collapse. The mood did.

The short version

The filed numbers show a company still generating nearly $2.9 billion in annual operating cash and expanding its net margin to 28%, even as revenue growth stalls. The stock is priced at roughly eight times its own decade-median earnings multiple, as if the stall is permanent. Those two readings reflect different assumptions about the durability of the growth stall; which assumption proves correct is what subsequent filings will need to resolve.

What the filings actually show

Zoetis filed its full-year 2025 10-K in February 2026, reporting revenue of $9.5 billion and a gross margin of 71.8%, meaning that for every dollar of sales, roughly 72 cents survived after the direct cost of making the product. That is a wide margin, wider than most drug companies manage, and it has held remarkably steady for five years. The net margin, the share of each revenue dollar left after every bill including taxes, reached 28% in 2025, the best in the company’s history as a standalone public entity.

Operating cash flow came in at $2.9 billion for 2025, more than the company’s entire net income, which is a healthy sign: it means earnings are backed by actual cash, not accounting adjustments. To put that in household terms, imagine a business that earns $100 in profit and collects $107 in real cash. That gap is a quality signal.

BullScope TerminalZoetis was the article. The engine is the product.Same yardsticks, any ticker: filed financials in, math-vs-mood out. Nothing here is advice; it is the evidence, organized.Run another company →

The most recent quarter, Q3 2026 filed November 5, tells a more complicated story. Total revenue slipped slightly from the same quarter a year earlier, not a crisis, but a reversal for a company that grew revenue every single year from 2020 through 2025. The U.S. companion animal business, historically the crown jewel, fell meaningfully as generic competitors moved into dermatology and veterinary clinic visits declined across categories year-to-date, according to management’s November 5 earnings release. Two things offset that: livestock revenue grew solidly, and diagnostics, the segment that sells testing equipment to clinics, grew even faster. The business is rebalancing, not breaking.

The math the market is ignoring

“The math” is what the filed fundamentals justify. “The mood” is what the market is currently paying. Right now, those two are unusually far apart.

Our data shows Zoetis trading at a price-to-earnings multiple, the price tag per dollar of annual profit, of 12.5 times. Its own decade median is 31.6 times. That puts the current multiple near the bottom of its own history, meaning the stock has been cheaper than this only a handful of times over the past ten years. The market is pricing Zoetis as if the stall in growth is not a chapter but an ending.

Management’s own guidance, narrowed on November 5, actually raised the earnings end of the range even as revenue guidance slipped. That combination, falling revenue but rising earnings-per-share guidance, reflects two things: a margin structure that is holding, and an aggressive buyback program that reduces the share count and mechanically lifts per-share earnings. Through the first nine months of 2026, Zoetis repurchased nearly $1.7 billion of its own stock, according to the Q3 2026 10-Q. That is a company allocating capital to buybacks at current prices, a signal that management’s internal valuation view differs from the market price, though buybacks can reflect capital-allocation policy as much as conviction about intrinsic value.

Where the bears have a point

The bear case is not invented. William Blair cut Zoetis from outperform to market perform in August 2026, and Leerink Partners moved to market perform in July, according to Tickeron’s November 2026 analysis. The concern is structural, not cyclical: pet owners are visiting veterinarians less often even as vet prices rise faster than general inflation, with veterinary services running well above the national inflation rate through August 2026. Higher prices with fewer visits means the volume of products dispensed per clinic is falling. That is the mechanism squeezing Zoetis’s U.S. companion animal revenue, and it does not fix itself quickly.

BullScope TerminalWant the full evidence sheet behind pieces like this?The terminal runs the complete workup: Zoetis and 500+ other names, on the same official data.See the evidence engine →

CFO James Saccaro said plainly on the November 5 call that the company would plan for 2027 “assuming no improvement in the macro environment, pet owner spending or competitive dynamics.” That is not a company signaling a sharp rebound. New product launches, including candidates in pet renal care, oncology, and cardiology, are expected to contribute only modestly until 2028, per the same earnings release.

The debt load is real too. The 2025 10-K shows total unsecured debt roughly equal to a full year of revenue. The net debt-to-EBITDA ratio, a measure of how many years of operating profit it would take to pay off the net debt, stood at a manageable but not negligible level through mid-2026, per the Q3 10-Q. That limits flexibility at exactly the moment the company might want to acquire its way into new growth.

The tension the filed data surfaces

Zoetis built its reputation on the idea that people treat their pets like family members and spend accordingly regardless of economic conditions. That thesis held through 2020, 2021, and 2022. It is bending now, not because pet ownership is declining, roughly 95 million U.S. households owned a pet as of 2025 per Forbes, but because the cost of veterinary care has risen fast enough to change behavior at the margin. Fewer clinic visits means fewer prescriptions filled, and that is the direct line from macroeconomics to Zoetis’s revenue line.

The livestock and diagnostics segments are growing and partially compensate. But they have historically carried lower margins than the companion animal business, so a revenue mix that shifts toward them tends to pressure overall profitability even if total revenue holds steady.

IF the filed trend in earnings-per-share, which has grown every year since 2020, continues at even a modest pace and IF the multiple reverts toward the midpoint of its own decade history, the same arithmetic that produced $82 would point to a materially higher range, but both conditions remain unresolved in the current data. If instead the U.S. companion animal headwinds prove durable and the pipeline takes longer than 2028 to contribute, the current multiple may not be as extreme as it looks. The data cannot yet answer which of those is right. Whether and how that gap closes, through price, through earnings, or through a sustained re-rating of the sector, is what subsequent filings and competitive data will need to resolve.

Reading the numbers

  • Net margin 28.2% (FY2025). What it is: the share of each revenue dollar left after every cost, including taxes. What it means here: Zoetis keeps 28 cents of every dollar it earns, up from 24.5 cents in 2020, even as revenue growth has slowed. Worked example: a corner store with $1 million in sales and this margin takes home $282,000 after all expenses. That is a high-quality business by any standard.
  • P/E of 12.5x vs. decade median of 31.6x (our data). What it is: the price-to-earnings multiple, the price tag per dollar of annual profit. What it means here: investors are paying less than half the historical going rate for each dollar of Zoetis earnings. Worked example: a rental property that historically sold for 31 times annual rent is now selling for 12.5 times. Either the rent is about to fall sharply, or the historical pricing relationship has not yet adjusted to new structural conditions, the filed data does not yet resolve which.
  • Q3 2026 adjusted EPS $1.75, up 3% (filed November 5, 2026). What it is: earnings per share, adjusted to remove one-time items, for the three months ended September 30. What it means here: even in a quarter where reported revenue fell 1%, the per-share profit number rose, because margins held and buybacks reduced the share count. Worked example: a pizza shop sells slightly fewer pizzas but cuts waste and buys out a partner, so each remaining owner’s slice of the profit grows.
  • Operating cash flow $2.9 billion (FY2025, 10-K filed February 2026). What it is: the actual cash the business generated from operations, before financing or investment activity. What it means here: the company collected more cash than its net income figure suggests, confirming the earnings are real. Worked example: a freelancer who invoices $100,000 and actually receives $107,000 in the bank is in better shape than one whose invoices and deposits match exactly.
  • Full-year 2026 revenue guidance $9.22 billion to $9.32 billion (management, November 5, 2026). What it is: management’s own forecast for the full calendar year, narrowed from a wider earlier range. What it means here: the midpoint implies roughly flat revenue compared to 2025’s $9.5 billion, a meaningful step down from the growth trajectory of prior years. Worked example: a business that grew sales 8% last year is now guiding for a 2% decline. The question is whether that is a pothole or a new road.

For the standing yardsticks on Zoetis: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: Zoetis.

Sources

  • Zoetis 10-Q, quarter ended September 30, 2026 (SEC EDGAR)
  • Zoetis 10-K, fiscal year ended December 31, 2025 (SEC EDGAR)
  • Zoetis Q3 2026 earnings press release, November 5, 2026
  • Zoetis Q3 2026 investor relations release
  • Zoetis full-year 2025 results press release
  • Tickeron: Zoetis earnings and pipeline analysis, November 2026
  • The Pet Budget: veterinary cost inflation through August 2026
  • Forbes Advisor: U.S. pet ownership statistics
  • GuruFocus: Zoetis valuation multiples, November 2026
BullScope publishes impersonal research for a general audience. Nothing here is personalized investment advice, and nothing here is a recommendation to buy or sell any security. As of publication, neither BullScope nor its operator holds a position in any security, covered or otherwise; we do not trade at all, and we accept no compensation from any company we cover. When a conflict of interest exists, we do not publish: companies that compensate our operator in any capacity, or about which our operator could hold nonpublic information, are barred from coverage automatically, as described in the conflicts policy in our methodology. Figures come from company filings and public data through our published methodology; forecasts are conditional scenarios, not predictions and not promises. Markets carry risk, including loss of principal. Consider your own situation, or consult a licensed adviser, before acting on anything you read.
BullScope TerminalYou just read Zoetis’ filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →
Moe Alsumidaie

Moe Alsumidaie

Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.

Recommended For You

Vertex Pharmaceuticals: The Business Keeps Growing. The Price Already Knows.

by Moe Alsumidaie
November 16, 2026
0

Goldman Sachs sees a stock worth $725. A Seeking Alpha contributor, writing the same week, called it a sell. Both are looking at the same filed numbers. That...

Read moreDetails

Biogen’s Crossroads: Five Years of Shrinking Revenue, a Stock Near Its All-Time High

by Moe Alsumidaie
November 2, 2026
0

Revenue has fallen every year since 2020. The stock just touched its 52-week high. Those two facts should not coexist, and the gap between them is the whole...

Read moreDetails

Amgen: The Stock Is Priced for a Future the Patent Cliff Might Not Allow

by Moe Alsumidaie
October 26, 2026
0

Amgen spent most of the 2010s as the quiet giant of biotech, printing cash from a handful of blockbuster drugs and returning nearly all of it to shareholders....

Read moreDetails

Abbott’s Split Personality: Revenue Climbs 14%, the Stock Falls Anyway

by Moe Alsumidaie
October 22, 2026
0

Abbott Laboratories spent most of the pandemic era as a Wall Street darling, its COVID test sales turning a steady healthcare conglomerate into a growth story. Then the...

Read moreDetails

The $14 Acquisition Price and the Arbitrage Gap the Market Is Pricing

by Moe Alsumidaie
October 16, 2026
0

The short version Sun Pharmaceutical agreed in April 2026 to buy Organon for $14.00 a share in cash, a deal Organon shareholders approved in July. The stock trades...

Read moreDetails
Next Post

Harrow's Ledger: Revenue Held, Profits Didn't

Please login to join discussion
BullScope
The Research Terminal
Run any stock through the BullScope evidence engine. Filings in, evidence out. Every number explains itself.
Open the Terminal
A BullScope product

Related News

Abbott to split Nutrition into independent company with $8.5 billion in sales by end of 2027

October 22, 2026

Harrow’s Ledger: Revenue Held, Profits Didn’t

November 11, 2026

Nike at $39: The Price That Doesn’t Match the Brand, or the Math

September 14, 2026
BullScope

BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.

Prefer BullScope.ai on Google

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

No Result
View All Result
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

Not enough quota to unlock this post
Unlock left : 0
Are you sure want to cancel subscription?
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.